Sell-Side Firms Lift AbbVie Price Targets, Estimates After Q3 Report
What happened
Multiple sell-side firms raised price targets and earnings estimates on AbbVie after the drugmaker's Q3 report, per a Benzinga roundup of analyst actions. Analysts characterized the quarterly print favorably, with a number of covering firms moving projections higher. ABBV gained 1.40% on the session while the broader tape declined.
The QL Read
In a risk-off tape — S&P 500 down 1.82%, breadth at 28.8% advancing, Tech off 4.89% — Health Care holds +0.45% as a defensive pocket. ABBV's QuantLogix composite sits at 85/100, with the stock up 1.40% at $294.89 against a declining market.
Not financial advice. QuantLogix is a research platform; nothing in this brief constitutes a recommendation to buy or sell any security. We summarize public news with attribution to the original publisher; visit the source above for the full original article.